Focused On-demand Library for Tryptase gamma

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q9NRR2

UPID:
TRYG1_HUMAN

ALTERNATIVE NAMES:
Serine protease 31; Transmembrane tryptase

ALTERNATIVE UPACC:
Q9NRR2; Q96RZ8; Q9C015; Q9NRQ8; Q9UBB2

BACKGROUND:
The protein Tryptase gamma, known alternatively as Serine protease 31 and Transmembrane tryptase, is encoded by the gene with accession Q9NRR2. This protein is part of the tryptase family, which plays a critical role in inflammation and immune system responses. The detailed functions of Tryptase gamma are still being elucidated, making it a focal point of scientific inquiry due to its potential impact on human health.

THERAPEUTIC SIGNIFICANCE:
The study of Tryptase gamma's role in biological processes is pivotal for identifying novel therapeutic targets. Given its involvement in inflammation and the immune system, targeting Tryptase gamma could lead to breakthrough treatments for related disorders. The ongoing research into Tryptase gamma holds promise for future drug discovery and development efforts.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.